SAN FRANCISCO--(BUSINESS WIRE)--MiLaboratories, a leader in RNA immune technologies, and Miltenyi Biotec, a global pioneer in biotechnology, are excited to announce a landmark partnership that ...
Syena secures exclusive license to Miltenyi Biotec’s PRAME TCR Syena, co-founded by Replay and MD Anderson in 2023, will develop an off-the-shelf PRAME TCR-NK cell therapy, with IND anticipated Q1 ...
Miltenyi Biotec has picked up a 51,800-square-foot office and research building in North San Jose for $34.1 million. The German biotech firm bought the two-story building at 2825 North First Street ...
In this webinar, Evelien Van Hamme and Elina Kuznecova will discuss core facility perspectives and their experiences with the MACSima spatial proteomics platform at the Flemish Institute for ...
Traditionally, imaging workflows required significant manual interaction and time investment from the user. The addition of automation has decreased user time commitment and increased data output.
Hosted on MSN
Miltenyi Biotec's ZAMTO Cell, claimed to be India's first dual-target CAR-T cancer therapy, expected by 2026
German biotechnology company Miltenyi Biotec has said that its CAR-T therapy, ZAMTO Cell, for B-cell lymphoma, is expected to be available in India by early 2026. CAR-T (Chimeric Antigen Receptor ...
(RTTNews) - Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi Biotec B.V. & Co. KG, which may appeal the Court's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback